Emile Sameh H, Horesh Nir, Garoufalia Zoe, Gefen Rachel, Wignakumar Anjelli, Wexner Steven D
Ellen Leifer Shulman and Steven Shulman Digestive Disease Center, Cleveland Clinic Florida, Weston, Florida, USA.
General Surgery Department, Colorectal Surgery Unit, Mansoura University Hospitals, Mansoura, Egypt.
J Surg Oncol. 2025 May;131(6):1081-1089. doi: 10.1002/jso.28043. Epub 2024 Dec 15.
Lymphovascular invasion (LVI) is an important prognosticator in rectal cancer (RC). We aimed to determine predictors for LVI in RC and incorporate them into a predictive risk score (PRS).
Case-control analysis of predictors of LVI in RC using data from a national database (2010-2019). Main outcome was LVI in RC and its predictors. Odds ratios of significant independent predictors of LVI were incorporated into a PRS.
55,178 patients were included (60.9% male; mean age: 61.3 years). LVI was detected in 10,446 (18.9%). Independent predictors were carcinomas that were signet-ring cell (OR: 1.98, p < 0.001), moderately differentiated (OR: 1.58, p < 0.001), poorly differentiated (OR: 3.9, p < 0.001), or undifferentiated carcinomas (OR: 4.1, p < 0.001), cN1 (OR: 1.21, p < 0.001), and cN2 (OR: 1.49, p < 0.001), stage and incorporated into a PRS (0-8). Incidence of LVI was 16.3% in the low-risk group, 27.8% in the intermediate-risk group, and 40.5% in the high-risk group (p < 0.001). The PPV of the score was 40.5%, NPV was 83.7%, accuracy was 82.4%, and specificity was 97.9%.
High-grade adenocarcinomas, signet-ring cell carcinomas, and lymph node involvement in clinical assessment were independently associated with LVI in RC. Incorporation of these predictors into a PRS conferred high specificity and good accuracy.
淋巴管侵犯(LVI)是直肠癌(RC)的一个重要预后指标。我们旨在确定直肠癌中LVI的预测因素,并将其纳入预测风险评分(PRS)。
利用国家数据库(2010 - 2019年)的数据对直肠癌中LVI的预测因素进行病例对照分析。主要结局是直肠癌中的LVI及其预测因素。将LVI的显著独立预测因素的比值比纳入PRS。
纳入55178例患者(男性占60.9%;平均年龄:61.3岁)。10446例(18.9%)检测到LVI。独立预测因素为印戒细胞癌(比值比:1.98,p < 0.001)、中分化癌(比值比:1.58,p < 0.001)、低分化癌(比值比:3.9,p < 0.001)或未分化癌(比值比:4.1,p < 0.001)、cN1(比值比:1.21,p < 0.001)和cN2(比值比:1.49,p < 0.001),将这些因素分期并纳入PRS(0 - 8分)。低风险组LVI发生率为16.3%,中风险组为27.8%,高风险组为40.5%(p < 0.001)。该评分的阳性预测值为40.5%,阴性预测值为83.7%,准确性为82.4%,特异性为97.9%。
高级别腺癌、印戒细胞癌以及临床评估中的淋巴结受累与直肠癌中的LVI独立相关。将这些预测因素纳入PRS具有高特异性和良好的准确性。